In a paper recently published in the European Journal of Internal Medicine, Schattner provided a thorough and in-depth review regarding the multiple, pleiotropic effects of colchicine, also highlighting its potential beneficial effects in coronavirus disease 2019 (COVID-19) [1]. In their commentary, Kow et al. [2] emphasize on the need for further trials with a longer treatment duration for the assessment of colchicine's therapeutic efficacy, dampening the initial enthusiasm. Previous meta-analyses of observational studies and randomized controlled trials demonstrated a mortality benefit with colchicine in patients with COVID-19, leading to the amendment of treatment protocols against the disease worldwide [3,4].
